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Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional varia-
tions in genotype prevalence. This poses a challenge to the improved development of
vaccines and pan-genotypic treatments, which require the consideration of global trends
in HCV genotype prevalence. Here we provide the first comprehensive survey of these
trends. To approximate national HCV genotype prevalence, studies published between
1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV
prevalence estimates from the Global Burden of Disease (GBD) project. We also gener-
ate regional and global genotype prevalence estimates, inferring data for countries lack-
ing genotype information. We include 1,217 studies in our analysis, representing 117
countries and 90% of the global population. We calculate that HCV genotype 1 is the
most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases),
approximately one-third of which are in East Asia. Genotype 3 is the next most preva-
lent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total
22.8% of all cases; genotype 5 comprises the remaining <1%. While genotypes 1 and 3
dominate in most countries irrespective of economic status, the largest proportions of
genotypes 4 and 5 are in lower-income countries. Conclusion: Although genotype 1 is
most common worldwide, nongenotype 1 HCV cases—which are less well served by
advances in vaccine and drug development—still comprise over half of all HCV cases.
Relative genotype proportions are needed to inform healthcare models, which must be
geographically tailored to specific countries or regions in order to improve access to
new treatments. Genotype surveillance data are needed from many countries to improve
estimates of unmet need. (HEPATOLOGY 2014;00:000-000)
H
epatitis C virus (HCV) is a globally prevalent
pathogen and a leading cause of death and
morbidity.1 The most recent estimates of dis-
ease burden show an increase in seroprevalence over
the last 15 years to 2.8%, equating to >185 million
infections worldwide.2 Persistent HCV infection is
associated with the development of liver cirrhosis,
hepatocellular cancer, liver failure, and death,3 and
HCV is now the most common cause of death in
HIV-positive patients on highly active antiretroviral
therapy.4 While the incidence rate of HCV infection is
apparently decreasing in the developed world, deaths
from liver disease secondary to HCV infection will
continue to increase over the next 20 years.5
Historically, HCV drug therapy has depended on
interferon-a (administered by injection) and ribavirin
over many months and is associated with severe side
effects. The resources required for treating HCV
patients with such drugs have been a considerable bar-
rier for healthcare systems in many low and/or lower-
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middle income countries, despite treatment outcomes
that are comparable to those in well-resourced set-
tings.6-8 That said, the coming decade should witness
a remarkable transformation in the treatment of HCV
infection. While the first generation of new direct-
acting antivirals (DAAs) were given in combination
with interferon and ribavirin, and thus added to the
burden of side effects,9,10 second-generation DAA
therapies with minimal side effects and shortened
courses of therapy are associated with cure rates of
more than 90% in Phase II or III studies.11 Moreover,
multiple DAA therapies targeting distinct HCV pro-
teins have been developed and, when given in combi-
nation, will obviate the need for interferon
treatment.12-14 Thus, if DAAs are made affordable, the
treatment of HCV across the globe will become a real-
istic option for the first time.
HCV exhibits an extraordinarily high degree of
genetic diversity—substantially greater than that of the
HIV-1 pandemic—creating a major challenge for the
development of both HCV vaccines and pan-genotypic
drug therapies.15 At present, the duration of treatment,
cure rates, and the need for adjuvant interferon and
ribavirin with the new DAA therapies remain depend-
ent in part on HCV genotype and subtype. Therefore,
the development of national treatment strategies using
DAA therapies requires a detailed understanding of
relative HCV genotype prevalence and subtypes.
Furthermore, the first prophylactive T-cell vaccines
that aim to prevent persistent HCV infection are cur-
rently in Phase II efficacy testing, with further candi-
dates moving into human studies.16 The first
generation of vaccines in development contain a
subtype-1b immunogen in viral vectors that are
deployed in a heterologous prime-boost regimen.17 In
countries with mixed genotype infection, crossreactive
immunity will depend on the generation of an
immune response that targets HCV antigens that are
conserved between genotypes. An alternative strategy,
however, would be to develop geographically tailored
vaccine immunogens for deployment at a country or
regional level where detailed information on viral sub-
types is available. Overall, the rational testing of HCV
vaccine candidates will require a comprehensive
country-level understanding of relative subtype
prevalence.
HCV strains are classified into seven recognized
genotypes (1-7) on the basis of phylogenetic and
sequence analyses of whole viral genomes.18 HCV
strains belonging to different genotypes differ at 30-
35% of nucleotide sites. Within each genotype, HCV
is further classified into 67 confirmed and 20 provi-
sional subtypes. Strains that belong to the same sub-
type differ at <15% of nucleotide sites.19 The
contemporary global geographic distribution of HCV
genotypes is complex. It has already been established
that a few subtypes—specifically 1a, 1b, 2a, and 3a—
are widely distributed across the globe and account
for a large proportion of HCV infections in high-
income countries. These so-called “epidemic sub-
types” are thought to have spread rapidly in the deca-
des prior to the discovery of HCV by way of infected
blood, blood products, injecting drug use, and other
routes.20-22 Many other HCV subtypes are considered
“endemic” strains; these are comparatively rare and
have circulated for long periods of time in more
restricted regions: endemic strains from genotypes 1
and 2 are primarily in West Africa, 3 in south Asia, 4
in Central Africa and the Middle East, 5 in Southern
Africa, and 6 in South East Asia.20,23,24 To date, only
one genotype 7 infection has been reported; it was
isolated in Canada from a Central African immi-
grant.25 The global distribution of HCV genetic vari-
ation has likely been influenced by historical and
contemporary trends in human migration. For exam-
ple, strains from West Africa appear to have been
transferred to the Americas by way of the trans-
Atlantic slave trade.26
Here we are the first to estimate the relative preva-
lence of HCV genotypes globally by region and by
country where data permitted. The data described
provide a platform for the rational deployment and
efficacy testing of new DAA therapies and vaccines for
HCV.
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Materials and Methods
We searched PubMed (www.pubmed.gov) for all
articles containing the terms “HCV” or “hepatitis c
virus” and “genotype” or “subtype” published between
1989 (the year that HCV was discovered) and 2013.
As a standardized genotype classification system was
not present before 1994, we converted HCV genotypes
or serotypes in articles published between 1989 and
1994 to the consensus nomenclature proposed by Sim-
monds et al.18 In many studies HCV cases were classi-
fied at the genotype level but not at the subtype level.
If articles contained the same patient cohort then this
cohort was only counted once. We recorded the
number of cases of each HCV genotype identified
along with the size of the study population. Some
individuals tested positive for more than one genotype;
in such cases each genotype identified was given its
own record. We did not include genotype 7 in the
analysis (see introduction).
We summed the total numbers of HCV cases
attributable to each genotype across all studies for
each country. This enabled a straightforward calcula-
tion of the relative proportion of HCV infections
comprised by each genotype. We then computed rela-
tive genotype frequencies for each Global Burden of
Disease (GBD) region as defined by the World
Health Organization (WHO).27 This allowed us to
combine our genotype frequency estimates with
recently published GBD estimates of overall HCV
seroprevalence to estimate the numbers of genotype-
specific cases within countries and regions as well as
globally. Countries for which we were unable to
obtain HCV genotype prevalence data were excluded
from calculations of regional proportions, although
their populations were included in the total popula-
tion size of each region when generating regional
genotype prevalence estimates. Since clinical studies
of new DAA therapies have routinely been stratified
by genotype 1 subtype, we examined the relative fre-
quency of genotype 1 cases that were confirmed as
either subtype 1a or 1b.
Mapping of genotype frequencies by country and
region was performed using ArcGIS 9.3 (www.esri.
com). The diversity of HCV genotypes present in
each country was computed using the Shannon
Diversity Index,28 resulting in a mappable score for
each country that is a function of the number and
relative frequency of genotypes identified within it.
We also further stratified genotype prevalence by
national income according to WHO income
categories.29
Results
In total, data from 1,217 studies were included in
the analysis. A complete reference list for these is pro-
vided in the Supporting Information. The 117 coun-
tries for which information on HCV genotypes was
found represent 90% of the world’s population and
are listed in Table 1 by WHO GBD region, along
with the number of studies for each country (the total
number of virus samples by country is provided in
Supporting Information Table S1). Unsurprisingly,
Western Europe and North America had the greatest
number of applicable studies. No studies meeting our
search criteria were available for the Oceania GBD
region (which does not include Australia), and the
number of studies with HCV genotype information is
relatively poor for the Caribbean, Central Latin Amer-
ica (outside of Mexico), and parts of Africa. Alto-
gether, HCV genotype frequency information is
available for 60% of the world’s countries (79 out of
196), representing nearly 90% of the world’s popula-
tion. The three most populous countries with no
HCV genotype information are Bangladesh, Malaysia,
and North Korea.
The relative prevalence of each HCV genotype by
GBD region is mapped using pie charts in Fig. 1 and
numerically in Table 2; the size of each chart is pro-
portional to the number of regional seroprevalent
HCV cases as estimated by Hanafiah et al.2 A com-
plete breakdown of HCV genotype frequency informa-
tion by country is provided in the Supporting
Information (Table S1). Globally, genotype 1 is esti-
mated to account for more HCV cases than any other
genotype at 83.4 million (46.2%), with over one-third
of genotype 1 cases located in East Asia. HCV geno-
type 3 is the next most common and is estimated to
account for 54.3 million (30.1%) cases globally,
approximately three-quarters of which occur in south
Asia. Genotypes 2, 4, and 6 are responsible for the
majority of the remaining cases of HCV worldwide,
with an estimated 16.5 million (9.1%), 15.0 million
(8.3%), and 9.8 million (5.4%) cases, respectively.
East Asia accounts for the greatest numbers of geno-
type 2 and genotype 6 HCV cases, while North Africa
and the Middle East have the largest number of geno-
type 4 cases. We estimate genotype 5 to be responsible
for the fewest HCV cases globally (1.4 million, <1%
of all HCV cases), the great majority of which occur
in Southern and Eastern sub-Saharan Africa.
Figure 2A displays the most common genotype by
country. Genotype 1 is the most common genotype in
85 of the 117 countries identified as having genotype
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information in our study, and is highly prevalent
worldwide. Of the 53% of genotype 1 cases for which
the subtype was specified, we find 99% to be attribut-
able to subtypes 1a and 1b (31% and 68%, respec-
tively). A map showing the dominance of subtype 1a
versus 1b in countries whose relative prevalence of
genotype 1 exceeds 25% is provided in the Supporting
Information (Fig. S5). We observed that genotype 2
dominated in West Africa, genotype 3 in south Asia
and parts of Scandinavia, genotype 4 in Central and
North Africa, Genotype 5 in South Africa, and geno-
type 6 in SE Asia.
The Shannon Diversity Index computed for each
country is mapped in Fig. 2B. A low score indicates
that most infections belong to one or two dominant
genotypes, whereas a high score indicates that infec-
tions are more evenly distributed across several geno-
types. The diversity of HCV genotypes varies
considerably across countries, with few discernable geo-
graphic patterns. Diversity is high in China and many
Southeast Asian countries, and also in Western Europe
and Australia.
The absolute number of genotyped cases, and the
numbers genotyped as a proportion of the population
included in our survey, is shown for each country in
Table S1 and Fig. 2C. Large sample sizes were avail-
able for the USA and many countries in Western
Table 1. Number of Studies per Country for Those Countries
Included in the Analysis; Grouped by GBD Region
Region/Country
Number
of Studies Region/Country
Number
of Studies
Andean Latin America 3 North Africa and
Middle East
95
Bolivia 1 Algeria 2
Peru 2 Egypt 19
Australasia 20 Iran (Islamic
Republic of)
9
Australia 19 Iraq 3
New Zealand 1 Israel 21
Caribbean 4 Jordan 1
Cuba 2 Kuwait 2
Martinique 1 Lebanon 3
Suriname 1 Libyan Arab Jamahiriya 1
Central Asia 18 Morocco 2
Azerbaijan 1 Qatar 2
Georgia 5 Saudi Arabia 4
Mongolia 8 Syrian Arab Republic 2
Tajikistan 1 Tunisia 6
Turkmenistan 1 Turkey 15
Uzbekistan 2 United Arab Emirates 3
Central Europe 43 South Asia 54
Albania 1 Afghanistan 1
Bulgaria 3 India 15
Croatia 6 Nepal 19
Czech Republic 1 Pakistan 19
Hungary 7 Southeast Asia 32
Montenegro 1 Brunei Darussalam 1
Poland 12 Cambodia 1
Romania 5 Indonesia 4
Slovakia 1 Lao People’s
Democratic
Republic
2
Slovenia 5 Myanmar 2
The former Yugoslav
Republic of Macedonia
1 Philippines 1
Central Latin America 29 Singapore 2
Colombia 3 Sri Lanka 1
Mexico 22 Thailand 11
Venezuela 4 Viet Nam 7
Central sub-Saharan Africa 7 Southern Latin
America
42
Central African Republic 2 Argentina 31
Congo 1 Chile 5
Democratic Republic
of the Congo
1 Uruguay 6
Equatorial Guinea 1 Southern sub-Saharan
Africa
6
Gabon 2 Namibia 1
East Asia 35 South Africa 5
China 35 Tropical Latin America 73
Eastern Europe 19 Brazil 73
Belarus 2 Western Europe 560
Estonia 2 Austria 38
Latvia 3 Belgium 19
Lithuania 3 Cyprus 2
Republic of Moldova 2 Denmark 10
Russian Federation 6 Finland 4
Ukraine 1 France 111
Eastern sub-Saharan Africa 9 Germany 62
Eritrea 1 Greece 32
Ethiopia 1 Iceland 1
Kenya 1 Ireland 9
Table 1. Continued
Region/Country
Number
of Studies Region/Country
Number
of Studies
Madagascar 1 Italy 155
Mozambique 1 Luxembourg 1
Sudan 1 Netherlands 1
Uganda 1 Norway 6
United Republic
of Tanzania
2 Portugal 4
High-income Asia
Pacific
46 Spain 55
Japan 42 Sweden 19
Korea, Republic of 4 Switzerland 14
High-income North
America
117 U.K. of Great Britain
and Northern Ireland
17
Canada 32 Western sub-Saharan
Africa
18
United States of America 85 Benin 1
Middle East and
North Africa
1 Burkina Faso 2
Bahrain 1 Cameroon 3
Cote d’Ivoire 1
Gambia 2
Ghana 1
Guinea 2
Guinea-Bissau 2
Nigeria 4
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Europe and Japan, whereas South America, Africa,
parts of Eastern Europe, and Asia were relatively
poorly sampled.
Figure 3A,B displays six maps (one for each geno-
type) of the relative prevalence among all HCV geno-
types by country. This figure reinforces the patterns
seen in Fig. 2A for genotype 1, displaying its wide
geographic extent and overall high prevalence world-
wide. The frequency of genotype 3 cases is notably
higher in south Asia but is comparatively lower in
Africa (Fig. 3A). Genotypes 2, 4, 5, and 6 are typically
more restricted in their extents. Genotype 4 frequen-
cies are highest from central Africa to the Middle East,
while genotype 5 only reaches higher frequencies in
southern Africa (Fig. 3B). Lastly, genotype 6 is present
at the highest frequencies in East and Southeast Asia,
but is the dominant genotype in only one country—
Laos (see Figs. 2A and 3B); it is also prevalent in
neighboring Vietnam. These patterns are broadly con-
sistent with previous informal summaries of the geo-
graphic structure of HCV genetic diversity.23,30,31
HCV cases in countries classified as high-income by
the WHO were comprised of 66% of genotype 1,
18% genotype 3, 12% genotype 2, and small propor-
tions of genotypes 4-6. Upper-middle income coun-
tries displayed a similar composition of HCV
genotypes, although with a greater proportion of geno-
type 6 cases (11%). In contrast, the low and lower-
middle income countries displayed relatively high pro-
portions of genotypes 4 and 5. For the genotype pro-
portions for all income classes, see the Supporting
Information (Table S2).
Discussion
The data presented here represent the most compre-
hensive effort to date to estimate the relative contribu-
tion of each HCV genotype to the global HCV
epidemic. Such data are crucial to inform future pre-
vention efforts (including vaccine design) as well as
policies to ensure global access to the new generation
Table 2. Global and Regional Estimates of HCV Seroprevalence Attributable to Each Genotype
WHO GBD Region
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5 Genotype 6 Regional HCV
N
(thousands) %
N
(thousands) %
N
(thousands) % N (thousands) %
N
(thousands) %
N
(thousands) %
Seroprevalence
Totals*
(thousands)
Andean Latin America 1,003 90.9 17 1.5 83 7.6 0 0.0 0 0.0 0 0.0 1,103
Australasia 388 54.2 34 4.7 280 39.2 9 1.3 0 0.0 3 0.5 715
Caribbean 450 92.6 15 3.2 17 3.5 4 0.8 0 0.0 0 0.0 486
Central Asia 2,100 66.6 148 4.7 906 28.7 0 0.0 0 0.0 0 0.0 3,155
Central Europe 1,548 89.2 1 0.1 164 9.4 22 1.3 0 0.0 0 0.0 1,736
Central Latin America 2,796 71.7 754 19.3 330 8.5 16 0.4 2 0.0 0 0.0 3,899
Central sub-Saharan
Africa
37 1.7 17 0.8 0 0.0 2,145 97.6 0 0.0 0 0.0 2,198
East Asia 32,082 58.0 8,444 15.3 5,762 10.4 40 0.1 0 0.0 8,982 16.2 55,311
Eastern Europe 4,023 65.1 270 4.4 1,881 30.4 6 0.1 0 0.0 0 0.0 6,181
Eastern sub-Saharan
Africa
1,187 37.3 294 9.2 288 9.1 978 30.7 436 13.7 0 0.0 3,183
High-income Asia Pacific 1,926 74.9 629 24.5 15 0.6 0 0.0 0 0.0 0 0.0 2,571
High-income North
America
3,595 75.8 567 12.0 492 10.4 55 1.2 6 0.1 26 0.6 4,742
North Africa and
Middle East
3,808 27.3 115 0.8 884 6.3 9,118 65.3 47 0.3 0 0.0 13,971
South Asia 12,889 23.2 1,333 2.4 39,706 71.6 1,413 2.5 80 0.1 55 0.1 55,475
Southeast Asia 4,910 57.0 1,572 18.2 1,331 15.4 77 0.9 0 0.0 729 8.5 8,619
Southern Latin America 876 87.0 58 5.7 65 6.5 5 0.5 4 0.4 0 0.0 1,008
Southern sub-Saharan
Africa
399 26.5 18 1.2 107 7.1 98 6.5 887 58.8 0 0.0 1,508
Tropical Latin America 1,802 69.3 89 3.4 699 26.9 7 0.3 3 0.1 0 0.0 2,600
Western Europe 3,169 59.0 583 10.8 1,332 24.8 262 4.9 26 0.5 2 0.0 5,374
Western sub-Saharan
Africa
4,427 65.7 1,550 23.0 0 0.0 761 11.3 5 0.1 0 0.0 6,743
Totals (excludes
Oceania)
83,413.4 46.2 16,509.0 9.1 54,345.0 30.1 15,014.5 8.3 1,496.3 0.8 9,798.6 5.4 180,576.8
*Regional HCV seroprevalence data from Hanafiah et al.2
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Fig. 1. Relative prevalence of each HCV genotype by GBD region. Size of pie charts is proportional to the number of seroprevalent cases as
estimated by Hanafiah et al.2
Fig. 2. (A) Countries by
the majority genotype found
across all associated stud-
ies. (B) Shannon Diversity
Index for study countries,
ranging from 0 (comprised
of larger proportions of a
few genotypes) to 1.2 (com-
prised of smaller proportions
of many genotypes). (C)
Number of genotyped virus
samples across all studies
by country.
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of interferon-free DAAs. Aside from countries entirely
lacking genotype information, our data highlight that
the evidence base for genotype prevalence is weakest in
Sudan, the Democratic Republic of the Congo, and
Tanzania, in terms of the number of viruses genotyped
as a proportion of their overall populations (Table S1;
Fig. 2C). Of the world’s countries for which genotype
data are missing, the largest populations are in Asia
(accounting for 3.6% of the global population), fol-
lowed by Africa (3.2% of the global population) and
Latin America (1.4% of the global population). These
regions typically represent areas of health neglect, and
should be a priority for further surveillance as disease
burden attributable to HCV is also likely to be high
in these locations.
It is important to note that the most prevalent
genotype in developed economies (genotype 1) is
also the most prevalent globally and should be well
served by interferon-free regimens of second-
generation DAA therapies with viral eradication rates
of >90%.13,32 Genotype 3, however, which accounts
for 30% of global infections, is not susceptible to
the first generation of DAA protease inhibitors, and
also appears less susceptible than other genotypes to
sofosbuvir, the most advanced second-generation
DAA therapy to date.33,34 Ultimately, should DAA
therapies currently in development prove to be
equally effective against all viral genotypes, viral gen-
otyping will cease to be relevant to therapy. Even so,
early data suggest that potential pan-genotypic com-
binations in late-stage development will continue to
require stratification by viral genotype to define the
optimal duration of drug therapy (e.g., sofosbuvir/
GS5816 or MK5172/8472).35
Fig. 3. Relative prevalence
of each genotype across all
virus samples by country.
Panel A: genotypes 1–3.
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One possible hypothesis for the current global dis-
tribution of genotype 1 is the chance association of
subtypes 1a and 1b with the international dissemina-
tion of contaminated blood and blood products during
the twentieth century, prior to the discovery of HCV
in 1989.22 The global dissemination of genotype 3 is
likely due to the association of subtype 3a with injec-
tion drug use21,36,37 and to population migration from
countries where subtype 3a is dominant, such as India
and Pakistan.38
Although HCV genotype 1 and 3 infections are
more prevalent than all other genotypes globally, geno-
types found more commonly in lower-income coun-
tries still account for a significant proportion of HCV
cases worldwide (Table S2). Specifically, genotype 2 is
most frequent in West Africa and parts of South
America (the latter likely reflecting population move-
ments resulting from the trans-Atlantic slave trade),26
while genotypes 4 and 6 are common in Central/
North Africa and East/Southeast Asia, respectively. We
estimate that genotypes 2, 4, and 6 combined account
for nearly one-quarter of all HCV cases globally.
Although initial data suggest that genotype 2 will be
relatively straightforward to treat in DAA interferon-
free regimens,33,34 the need for more data about geno-
type 4 and 6 infections is a priority in order to inform
local policies, especially in areas of highest prevalence.
Stratification by viral genotype at a national and
regional level, and a better understanding of viral
diversity within target populations, will also critically
inform the rational design and testing of HCV vac-
cines. We have shown that diversity tends to be high
Fig. 3. (Continued). Panel B:
genotypes 4–6.
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in high-prevalence countries. The first T-cell vaccine,
which hosts a genotype-1 immunogen, is currently
undergoing efficacy testing in intravenous-drug user
(IVDU) populations in Baltimore and San Francisco,
where genotype 1 infection is dominant. Phase I clini-
cal data suggest that the generation of T cells that tar-
get multiple viral genotypes using this vaccine is
possible.17 Still, the roll-out of this and other HCV
vaccines to other countries will require a detailed
understanding of HCV genetic diversity within new
target populations. Genotype diversity is particularly
high in China and many Southeast Asian countries,
and also in Western Europe and Australia, perhaps as
a result of population immigration from Africa and/or
Asia.39 In countries like these, vaccine efficacy at a
population level would be dependent on the genera-
tion of crossreactive immunity; an alternative approach
could also be the development of vaccines hosting dif-
ferent immunogens. In contrast, in countries where
diversity is constrained such as Egypt (low diversity
here is likely the result of the rapid amplification of
subtype 4a during the twentieth century as a result of
specific iatrogenic events),40 vaccine immunogens
designed to most closely align with population HCV
sequence may be the optimal strategy.
Our study is intended as a comprehensive literature
survey and is not intended as a statistically formal
meta-analysis. PubMed is the world’s largest medical
library, and so we are confident in the comprehensive-
ness of our published literature base. However, we rec-
ognize that there are limitations within our dataset,
and also that there may be some useful unpublished
reports that were excluded from this study. Foremost
among these is potential selection bias, since not all
studies included were surveys of the general population
(or proxies thereof, such as prospective blood donors).
Thus, some risk groups associated with specific geno-
types may be more readily sampled than others, and
the impact of this may be strongest in those countries
with the fewest number of genotyped cases. A mecha-
nism for removing studies of certain risk groups would
be required, and such a subjective decision could lead
to additional sources of bias. In addition, we have not
stratified studies according to the methodology used to
genotype patients. Since the HCV RNA 50UTR
(untranslated region) is the most common target for
diagnostic HCV RNA assays, it is also the viral region
most commonly used to define viral genotype. While
this region is relatively conserved, single nucleotide dif-
ferences assessed using sequencing or probe-based
assays are most commonly used in assays to define
viral genotype.41 Importantly, these assays have been
deemed adequate for current clinical applications.
Although clinical assays that assess viral subtype also
rely on 50UTR as a substrate, the accuracy of HCV
subtyping will be improved by additional sequencing
of other viral regions such as core42 and NS5B.43
Overall, we believe errors arising from the misassign-
ment of viral genotype to be limited. As a consequence
of all the above, we have chosen not to provide confi-
dence limits for our prevalence estimates, as we believe
any such measure of uncertainty would be inappropri-
ate without an explicit statistical sampling model. This
is an important task for future refinements of the val-
ues reported here. Lastly, we have not addressed the
contribution of each HCV genotype to the overall
burden of morbidity and mortality due to acute infec-
tion, liver failure, or cirrhosis.
Our estimates of relative genotype prevalence are
dependent on viral genetic data in association with
global and national estimates of HCV prevalence based
on seropositivity, which includes instances of cleared
infections.1 Our estimates of relative genotype preva-
lence could be affected, therefore, if one genotype is
cleared more readily than another. Comparison of
spontaneous clearance rates between genotypes is unre-
liable since these have largely relied on the assessment
of outbreak studies of single genotypes in distinct
patient populations44 and are therefore subject to
cohort bias. Consequently, the absolute number of
cases attributable to each genotype reported here is
most correctly interpreted as the number of infections
of each genotype—past and present—that induced the
seropositivity observed. Thus, if a country has under-
gone rapid, recent, and significant changes in relative
genotype frequency, our absolute counts may be a
poor proxy for the genotypes that characterize future
incidence.
Although genotypes 1 and 3 account for the major-
ity of infections worldwide, HCV strains belonging to
the rarer genotypes 2, 4, 5, and 6 can increase rapidly
in prevalence if they happen to become associated with
efficient routes of transmission. The high prevalence
and dominance of subtype 4a in Egypt is widely
believed to have resulted from its spread by way of
unsafe injections during past anti-schistosomal public
health campaigns.40 Other subtypes have been ampli-
fied locally and regionally after being introduced into
networks of injection drug users—for example, subtype
4d in Europe45,46 and subtype 6a in Vietnam and
Hong Kong.47 These observations suggest that under
the right circumstances, most, if not all, HCV geno-
types have epidemic potential. They also suggest that
social, behavioral, and demographic factors (including
HEPATOLOGY, Vol. 00, No. 00, 2014 MESSINA ET AL. 9
international migration) are more important than viral
genetic variation in determining the global prevalence
of different genotypes.
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